Trials
Search / Trial NCT06422637

A Prospective Interventional Study on Early Screening for Lung Cancer Using Liquid Biopsy

Launched by THE FIRST AFFILIATED HOSPITAL OF GUANGZHOU MEDICAL UNIVERSITY · May 19, 2024

Trial Information

Current as of February 18, 2025

Not yet recruiting

Keywords

Lung Cancer Liquid Biopsy

ClinConnect Summary

This study is the first international prospective interventional study for lung cancer screening. It designates the "Love Lung Program" using Low-Dose Computed Tomography (LDCT) screening as the control group and the MERCURY screening group as the intervention group. Participants from the general population were enrolled and randomly assigned to either group in a 1:1 ratio. The MERCURY group plans to collect baseline peripheral blood samples from 2,972 individuals for whole genome sequencing (WGS) based on plasma circulating free DNA (cfDNA). This will facilitate a comprehensive analysis of...

Gender

ALL

Eligibility criteria

  • Inclusion Criteria:
  • Age greater than 40 years old and less than 75 years old, regardless of gender.
  • Sign the informed consent form.
  • Exclusion Criteria:
  • Pregnant women;
  • Individuals currently diagnosed with any tumors other than lung cancer, or who have a history of cancer;
  • Those who have undergone LDCT/CT screening within the past 1-3 years;
  • Individuals currently suffering from a febrile illness, or who have had an acute inflammatory disease episode requiring internal medicine treatment within the last 14 days prior to blood draw;
  • Individuals who have taken corticosteroids orally or through intravenous injection within the 14 days prior to blood draw;
  • Organ transplant recipients or those who have previously received a non-autologous (allogeneic) bone marrow or stem cell transplant;
  • Individuals in poor health or not suitable for blood drawing;
  • Any other clinically significant disease or condition considered by the researchers to potentially affect adherence to the protocol, impact the patient's ability to provide informed consent, or render the patient unsuitable for participation in the clinical trial.

Trial Officials

Jianxing He, MD

Principal Investigator

Department of Medical Oncology of Respiratory, Guangxi Medical University Cancer Hospital

About The First Affiliated Hospital Of Guangzhou Medical University

The First Affiliated Hospital of Guangzhou Medical University is a leading clinical research institution located in Guangzhou, China, renowned for its commitment to advancing medical knowledge and improving patient care through innovative research. As a comprehensive teaching hospital, it integrates clinical practice, education, and research, fostering a multidisciplinary approach to healthcare. The hospital is equipped with state-of-the-art facilities and a team of experienced professionals dedicated to conducting high-quality clinical trials across various therapeutic areas. By leveraging its extensive expertise and resources, the First Affiliated Hospital aims to contribute significantly to the development of new treatments and therapies, enhancing health outcomes for patients both locally and globally.

Locations

Guangzhou, Guangdong, China

People applied

Timeline

First submit

Trial launched

Trial updated

Estimated completion

Not reported

Discussion 0